Jeremy Skillington of Poolbeg Pharma: POLB 001 LPS human challenge clinical trial successfully completed
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington, CEO of says they have now received the initial results, having completed the LPS human challenge clinical trial for POLB 001, and it was found to be safe and well tolerated.
Highlights
· No further clinical activity is required to complete the objectives of the trial, bringing the recruitment and clinical phase to a close on schedule
· No serious adverse events reported. POLB 001 was found to be safe and well tolerated
· Data analysis has commenced and full data read-out is expected in Q2 2023
· The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.